Bioequivalence study comparing Quetiapine extended release tablets 400 mg (Pharmathen S.A.) to the reference listed drug Seroquel® tablets under fasting conditions after multiple dose administration at steady state in adult schizophrenic patients stabilized on Quetiapine 400 mg per day
- Conditions
- Health Condition 1: null- Adult schizophrenic patients (stabilized on Quetiapine 400 mg per day)Health Condition 2: F208- Other schizophrenia
- Registration Number
- CTRI/2012/09/002956
- Lead Sponsor
- Pharmathen SA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 51
1.Written informed consent for participation in the study by the patient and Patientâ??s Legally Acceptable Representative (LAR)
2.Patient has a documented clinical diagnosis of schizophrenia (DSM IV-TR)
3.Patient should be on a stable dose of Quetiapine 400 mg per day for at least 14 days prior to screening
4.Having a Body Mass Index (BMI) between 18 and 30 (both inclusive), calculated as weight in kg/height in m2
5.Able to comply with study procedures in the opinion of the investigator
6.In case of female patient the serum pregnancy test at screening visit and urine pregnancy test at day 1 (before dosing) must be negative
7.Sexually active women, unless surgically sterile (at least 6 months prior to Study drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to Study drug administration] sexual partner) for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug
8.In case of Male patients: Either partner or patient must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug
(It is investigatorâ??s responsibility to ensure that above points regarding an effective method of avoiding pregnancy are discussed with patient/LAR in detail and patient agreed for this and it is documented in source document. The investigator should ensure that the patient is using an effective method of avoiding pregnancy as per protocol)
1.Known hypersensitivity or idiosyncratic reaction to Quetiapine and its excipients
2.Current or relevant history of serious, severe or unstable psychiatric illness except schizophrenia
3.Presence of Postural Hypotension (Defined as systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within three minutes of standing up)
4.History of syncope or orthostatic hypotension
5.Ingestion of any medication other than listed below at any time in 10 days before the first study drug administration. In any such case Patient selection will be at the discretion of the Principal Investigator / Medical Expert. Following is the list of permissible medications, provided, the patients are on a stable regimen at least 14 days prior to and throughout the study: Alprazolam, Fluoxetin, Imipramine, Haloperidol and Risperidone
6.A recent history of alcoholism (less than 2 years) or daily consumption of moderate (180 ml / day) alcohol use, or consumption of alcohol or alcoholic products within 48 hour of receiving study medication or inability to abstain from alcohol during the study
7.Smokers who has inability to abstain from smoking during the study
8.Donation of blood (1 unit or 350 ml) within 90 days prior to receiving the first dose of study medication or during the study
9.A positive hepatitis screen including HBsAg, HCV and HAV IgM antibodies
10.Known case of HIV infection
11.Supine blood pressure less than 110/70 mmHg or pulse rate less than 60 or more than 100 beats per minute at screening
12.Any condition/ Abnormal baseline findings that in the investigatorâ??s judgement might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study
13.The receipt of an investigational product or participation in a drug research study within a period of 30 days prior to the first dose of study medication
Note: Elimination half-life of the study drug should be taken into consideration for inclusion of the Patient in the study.
14.Psychosis judged to be the direct physiological effect of an abused medication or substance
15.Patients with a known intolerance or lack of response to previous treatment with Quetiapine
16.Positive testing for the drugs of abuse (amphetamines, barbiturates ,benzodiazepines, cocaine, morphine , marijuana) done by urine drug scan at day 0 (except for Alprazolam which is a permissible medication)
17.History of Organic Brain Disorder
18.Hospitalisation for an exacerbation of schizophrenia within two months prior to screening and during the screening period
19.Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
20.Patients with the following cardiac conditions are excluded:
•Recent myocardial infarction (12 months)
•QTc prolongation (screening electrocardiogram with QTc 450 msec for men,QTc 470 msec for women)
•History of QTc prolongation or using concomitant medications which prolong QTc interval
•Sustained cardiac arrhythmia or history of sustained cardiac arrhythmia
•Uncompensated congestive heart failure
•Complete left bundle branch block
•First-degree heart block with PR interval 0.22 seconds
21.Pre
Study & Design
- Study Type
- BA/BE
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the bioavailability and characterise the pharmacokinetic profile of the Sponsorâ??s formulation (Quetiapine Extended Release tablets 400 mg) with respect to the reference formulation (Seroquel® Prolong 400 mg tablets) in adult Schizophrenic patients (stabilized on Quetiapine 400 mg per day) under fasting conditions and to assess the bioequivalenceTimepoint: At the end of study
- Secondary Outcome Measures
Name Time Method To monitor the safety of the patients who are exposed to the investigational medicinal productTimepoint: Safety assessment will be done till the end of study